On March 20, the US Supreme Court delivered a decision in Mayo v. Prometheus that may have profound implications on the biotech sector. Already struggling with innovation funding, finding the next "big idea" just became significantly harder. Many hoped personalized medicine would represent growth for the biotech sector. Now the Supreme Court decision appears to add more uncertainty into an already-complex equation - one that certainly warrants greater discussion and understanding by all involved in the life sciences and novel technologies generally.
The LES Spring Meeting, in Boston on May 15-17, will focus precisely on this concept of finding the next "big idea." Boston, one of the unquestioned innovation hubs on the planet, is the ideal setting for what will be a rare opportunity to work interactively with key thought leaders and senior industry executives to explore how to solve the innovation gap through licensing.
Here are four reasons why I think you should not miss this meeting:
#1 Licensing to Solve the Innovation Gap Panel
Daniel Behr (SVP at Acces BridgeGap Ventures), Jeff Elton (CEO & Co-Founder of KEW Group, LLC) and Robert Langer (David H. Koch Institute Professor at MIT) will kick off the meeting with an in-depth and interactive exploration of our unprecedented times. They'll review what works and what doesn't any longer, and how the biotech business model can be structured to drive maximum value creation from scientific innovation.
#2 George Scangos, CEO of Biogen IDEC
His keynote speech will address how licensing has been key to building a strong, innovative R&D pipeline for the company. Focusing on models of collaboration and flexibility in licensing strategy, Dr. Scangos will speak to recent transactions such as the collaboration with Portola Pharma (Syk inhibitor), ISIS (spinal muscular atrophy), and Samsung (biosimilars).
#3 Robert Coughlin, President & CEO of the Massachusetts Biotechnology Council
Something clearly is working in Boston and the state of Massachusetts. It's arguably the "go-to" innovation hub on the planet, and home to some of the biggest researchers, entrepreneurs, VCs and corporate names in the life sciences. The value of innovation created in the state is staggering, so it pays to listen and learn from their example. During his talk at the Networking Reception at the Museum of Fine Arts, Mr. Coughlin will share the local secrets of success.
#4 Tales from the Trenches - a Spotlight on Deals in the News
David Meeker (President & CEO Genzyme), Michal Preminger (Executive Director of Office of Technology Development, Harvard Medical School Office), Ariel Jasie (Senior Director Business Development, Celgene) and Nagesh Mahanthappa (VP Corporate Development & Operations, Avila Therapeutics) have all generated that "wow" factor that dealmakers can't help but notice. They've been involved in some recent significant and innovative transactions, and have insight to share that is priceless. Their "tales from the trenches" will provide practical information and knowledge to help you enable your own deal making.
Our goal is to provide a clear picture of the business environment, opportunities, and deals. The line-up of plenary speakers, workshops and unparalleled networking opportunities makes this a must-attend event for any professional in life sciences and related fields.
I encourage you to review the entire program and register now to take advantage of our Super Early Rate by March 30!
Sincerely,
Mark Nawacki
VP Business & Corporate Development
Paladin Labs Inc.
and
LES 2012 Spring Meeting Chair
No comments:
Post a Comment